2'-modified oligonucleotides for antisense therapeutics

Current Topics in Medicinal Chemistry

Volumn 7, Issue 7, 2007, Pages 641-649

  Prakash, Thazha P ^a   Bhat, Balkrishen ^a  

^a ISIS PHARMACEUTICALS   (United States)

Author keywords

Antisense oligonucleotides; Arabino nucleic acids; DNA decamer duplex; RNA affinity; RNase H enzyme

Indexed keywords

2' DEOXY 2' FLUORO 2 THIOTHYMIDINE OLIGONUCLEOTIDE; 2' DEOXY 2' FLUORO 5 METHYL 2 THIOURIDINE OLIGONUCLEOTIDE; 2' O [2 (AMINO) 2 OXOETHYL]OLIGONUCLEOTIDE; 2' O [2 (DIMETHYLAMINO) 2 OXOETHYL]OLIGONUCLEOTIDE; 2' O [2 (GUANIDINIUM)ETHYL]OLIGONUCLEOTIDE; 2' O [2 (METHOXY)ETHYL] 5 METHYL 2 THIOURIDINE OLIGONUCLEOTIDE; 2' O [2 (METHOXY)ETHYL]OLIGONUCLEOTIDE; 2' O [2 (METHYLAMINO) 2 OXOETHYL]OLIGONUCLEOTIDE; 2' O [2 (METHYLTHIO)ETHYL]OLIGONUCLEOTIDE; 2' O [2 (N ISOPROPYL N METHYLAMINOOXY)ETHYL]OLIGONUCLEOTIDE; 2' O [2 (N,N DIETHYLAMINOOXY)ETHYL]OLIGONUCLEOTIDE; 2' O [2 (N,N DIMETHYLAMINOOXY)ETHYL]OLIGONUCLEOTIDE; 2' O [2 [2 (DIMETHYLAMINO)ETHYL]AMINO] 2 OXOETHYL]OLIGONUCLEOTIDE; 2' O [2 [2 (N,N DIMETHYLAMINO)ETHOXY]ETHYL]OLIGONUCLEOTIDE; 2' O [2 [N METHYL N (2 AMINOETHYL)AMINOOXY]ETHYL]OLIGONUCLEOTIDE; 2' O AMINOPROPYLOLIGONUCLEOTIDE; 2' O METHOXYETHYL 2 THIOTHYMIDINE OLIGONUCLEOTIDE; ANTISENSE OLIGONUCLEOTIDE; ARABINO NUCLEIC ACID; BICYCLIC NUCLEIC ACID; FOMIVIRSEN; NUCLEIC ACID; OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE; OLIGONUCLEOTIDE; UNCLASSIFIED DRUG;

ANTISENSE THERAPY; BINDING AFFINITY; CHEMICAL MODIFICATION; CONFORMATIONAL TRANSITION; CRYSTAL STRUCTURE; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG SYNTHESIS; HUMAN; NONHUMAN; REVIEW; STRUCTURE ACTIVITY RELATION;

ANIMALS; CARBOHYDRATES; HUMANS; NUCLEOTIDES, CYCLIC; OLIGONUCLEOTIDES, ANTISENSE; RIBONUCLEASE H, CALF THYMUS; RNA;

EID: 34247586674     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802607780487713     Document Type: Review

References (60)

1. Dias, N.; Stein, C. A. Antisense Oligonucleotides: Basic Concept and Mechanism. Mol. Cancer Theraput. 2002, 1, 347-355.
2. Crooke, S. T., Antisense Drug Technology, Marcel Dekker, New York, 2001, pp. 92
3. Manoharan M. 2′-Carbohydrate Modifications in Antisense Oligonucleotide Therapy: Importance of Conformation, Configuration and Conjugation. Biochim. Biophys. Acta 1999, 1489, 117-130.
4. Kurreck, J. Antisense Technologies Improvement Through Novel Chemical Modifications Eur. J. Biochem. 2003, 270, 1628-1644
5. Mangos, M. M.; Damha, M. J. Flexible and Frozen Sugar Modified Nucleic Acids Modulation of Biological Activity Through Furanose Ring Dynamics in the Antisense Strand. Curr. Top. Med. Chem. 2002, 2 1147-1171.
6. Crouch, R. J.; Dirksen, M. L. Nucleases, Vol. 14, Cold Spring Harbor Monograph Series, Plainview, 1982, pp. 211-254.
7. Nakamura, H.; Oda, Y.; Iwai, S.; Inoue, H.; Ohtsuka, E.; Kanaya, S.; Kimura, S.; Katsuda, C.; Katayanagi, K.; Morikawa, K.; Miyashiro, H.; Ikehara, M. How does RNase H recognize DNA-RNA hybrid. Proc. Natl. Acad Sci. USA 1991, 88, 11535-11539.
8. Eckstein F. Phosphorothioate Oligonucleotides: What is their Origin and What is Unique About Them? Antisense Nucleic Acid Drug Dev. 2000, 10, 117-121.
9. Levin, A. A. A Review of Issues in the Pharmacokinetics and Toxicology of Phosphorothioate Antisense Oligonucleotides. Biochim. Biophys. Acta 1999, 1489, 69-84.
10. Freier, S. M.; Altmann, K. H. The Ups and Downs of Nucleic Acid Duplex Stability: Structure-Stability Studies on Chemically-modified DNA:RNA Duplexes. Nucleic Acids Res. 997, 25, 4429-4443.
11. Crooke, S.T. Phosphorothioate Oligonucleotides, in: Therapeutic Applications of Oligonucleotides, Crooke, S.T. (Ed.), R. G. Landes, Austin, 1995; p. 79.
12. Mesmaeker, A. D.; Häner, R.; Martin, P.; Moser, H. E. Antisense Oligonucleotides. Acc. Chem. Res. 1995, 28, 366-374
13. Guschlbauer, W.; Jankowski, K. Nucleoside Conformation is Determined by the Electronegativity of the sugar substituent. Nucleic Acids Res. 1980, 8, 1421-1433.
14. Saenger, W. Principles of Nucleic Acid Structure; Springff-Verlag: New York, 1983.
15. Rozners, E.; Moulder, J. Hydration of short DNA, RNA and 2′-O-Me Oligonucleotide Determined by Osmotic Stressing. Nucleic Acids Res. 2004, 32, 248-254.
16. Inoue, H.; Hayase, Y.; Imura, A; Iwai, S.; Miura, K.; Ohtusuka, K. Synthesis and Hybridization Studies on Two Complementary Nona(2′-O methyl) ribonucleotides. Nucleic Acids Res. 1987, 15, 6131-6148.
17. Kawasaki, A. M.; Casper, M. D.; Freier, S. M.; Lesnik, E. A.; Zounes, M. C.; Cummins, L. L.; Gonzalez, C.; Cook, P. D. Uniformly Modified 2′-Deoxy-2′-Fluoro Phosphorothicate Oligonucleotides as Nuclease-resistant Antisense Compounds with High Affinity and Specificity for RNA Targets. J. Med. Chem. 1993, 36 831-841.
18. Lesnik, E. A., Guinosso, C. J.; Kawasaki, A. M.; Sasmor, H.; Zounes, M.; Cummins, L. L.: Ecker, D. J.; Cook, P. D.; Freier, S. M. Oligodeoxy-nucleotides Containing 2′-O-Modified Adenosine: Synthesis and Effects on Stability of DNA:RNA Duplexes. Biochemistry 1993, 32, 7832-7838.
19. Martin P. Ein neuer zugang zu 2′-O-Alkylribonucleosiden und Eigenschanften deren Oligonucleotide. Helv. Chim. Acta 1995 78, 486-504.
20. Teplova, M.; Miasov, G.; Tereshko, V.; Inamati, G. B.; Cook, P. D.; Manoharan, M.; Egli, M. Crystal Structure and Improved Antisense Properties of 2′-O-(2-methoxyethyl) RNA. Nat. Struct. Biol. 1999, 6, 535-539.
21. Tereshko, V.; Portmann, S.; Tay, E. C.; Martin, P.; Natt, F.; Altmann, K. H.; Egli, M. Correlating Structure and Stability of DNA Duplexes with Incorporated 2′-O-Modified RNA Analogues. Biochemistry 1998, 37, 10626-10634.
22. Prakash, T. P.; Manoharan, M.; Kawasaki, A. M.; Fraser, A. S.; Lesnik, E. A.; Sioufi, N.; Leeds, J. M.; Teplova, M.; Egli, M. 2′-O [2-(Methylthio) ethyl]-Modified Oligonucleotide: An Analogue of 2′-O-[2-(Methoxy)-ethyl]-Modified Oligonucleotide with Improved Protein Binding Properties and High Binding Affinity to Target RNA. Biochemistry 2002, 41, 11642-11648.
23. Prakash, T. P.; Manoharan, M.; Kawasaki, A. M.; Lesnik, E. A.; Owens, S. R.; Vasquez, G 2′-O-[2-[(N,N-Dialkylamino)oxy]ethyl] Modified Antisense Oligonucleotides. Org. Lett. 2000, 2 25), 3995-3998.
24. Prakash, T. P.; Andrew, K. M.; Fraser, A. S.; Vasquez, G.; Manoharan, M. Synthesis of 2′-O-[2-[(N,N-dimethylamino)oxy]ethyl modified nucleosides and oligonucleotides. J. Org. Chem 2002 67, 357-369.
25. Prakash, T. P.; Kawasaki, A. M.; Lesnik E. A.; Sioufi, N.; Manoharan, M. Synthesis of 2′-O-[2-(dialkylamino)oxy]ethyl]-Modifted Oligonucleotides: Hybridization Affinity, Resistance to Nuclease, and Protein Binding Characteristics. Tetrahedron 2003, 59 7413-7422.
26. Prakash, T. P.; Kawasaki, A. M.; Lesnik,E. A.; Owens, S. R.; Manoharan, M. 2′-O-[2-(Amino)-2-oxoethyl] Oligonucleotides. Org. Lett. 2003, 5, 403-406.
27. Griffey, R. H.; Monia, B. P.; Cummins, L. L.; Freier, S. F.; Greig, M. J.; Guinosso, C. J.; Lesnik, E.; Manalili, S. M.; Mohan, V.; Owens, S.; Ross, B. R.; Sasmor, H.; Wancewicz, E.; Weiler, K.; Cook, P. D. 2′- O-Aminopropyl Ribonucleotides: A Zwittterionic Modification that Enhances the Exonuclease Resistance and Biological Activity of Antisense Oligonucleotides. J. Med. Chem. 1996, 36, 5100-5109.
28. Teplova, M.; Wallace, S. T.; Minasov, G.; Tereshko, V.; Symons, A.; Cook, P. D. Structural origin of exonuclease resistance of zwitterionic RNA. Proc. Nat. Acad. Sci. USA 1999, 96, 14240-14245.
29. Praksh, T. P.; Manoharan, M.; Fraser, A. S.; Kawasaki, A. M.; Lesnik, E. A.; Owens, S. R. Zwitterionic Oligonucleotides with 2′-O-[3-(N,N-dimethylamino)propyl]-RNA Modification Synthesis and Properties. Tetrahedron Lett. 2000, 41, 4855-4859.
30. Manoharan, M.; Prakash, T. P.; Barber-Peoc'h, I.; Bhat, B.; Vasquez, G.; Ross, B. S.; Cook, P. D. N-(2-Cyanoethoxycarbonyloxy)succinimide: A New Reagent for Protection of Amino Groups in Oligonucleotides. J. Org. Chem. 1999, 64(17), 6468-6472.
31. Prhavc, M.; Prakash, T. P.; Minasov, G.; Cook, P. D.; Egli, M.; Manoharan, M. 2′-O-[2-[2-(N,N-dimethylamino ethoxy]ethyl] modified oligonucleotides: Symbiosis of charge interaction factors and stereoelectronic effect. Org. Lett. 2003, 5, 2017-2020.
32. Prakash, T. P.; Pueschl, Ask P.; Lesnik, E.; Mohan, V.; Tereshko, V.; Egli, M.; Manobaran, M. 2′-O-[2-(Guanidinium)ethyl]-Modified Oligonucleotides: Stabilizing Effect on Duplex and Triplex Structures. Org. Lett. 2004, 6, 1971-1974.
33. Egli, M.; Minasov, G.; Tereshko, V.; Pallan, P. S.; Teplova, M.; Inamati, G.; Lesnik, E.; Owens, S., Ross, B.; Prakash, T. P.; Manoharan, M. Probing the Influence of Stereoelectronic Effects on the Biophysical Properties of Oligonucleotides: Comprehensive Analysis of the RNA Affinity, Nuclease Resistance and Crystal Structure of Ten 2′-O Ribonucleic Acid Modifications. Biochemistry 2005, 44, 9045-9057.
34. Rajeev, K. G.; Prakash, T. P.; Lesnik, E. A.; Manoharan, M. Synthesis and Properties of 2′-Modified-2-thiothymidine Oligonucleotides. Org. Lett. 2003, 5, 2017-2020.
35. Ginnaris, P.; Damha, M. J. Hybridization Properties of Oligoarabino-nucleotides. Can. J. Chem. 1994, 72, 909-918.
36. Noronha, A. M.; Wilds, C. J.; Lok, C-N.; Viazovkina, K.; Arion, D.; Parniak, M. A.; Damha, M. J. Syntheisis and Biophysical Properties of Arabinonucleic Acids (ANA): Circular Dichroic Spectra, Melting Temperature, and Ribonuclease H Susceptibility of ANA/RNA Hybrid Duplexes. Biochemistry 2000, 39, 7050-7062.
37. Lima, W. F.; Nichols, J. G.; Wu, H.; Prakash, T. P.; Migawa, Mike T.; Wyrzykiewicz, T. K.; Bhat, B.; Crooke, S.T. Structural Requirements at the Catalytic Site of the Heteroduplex Substrate for Human RNase H1 Catalysis. J. Biol. Chem. 2004, 279, 36317-36326.
38. Wu, H.; Lima, W. F.; zhang, H., Fan, A.; Sun, H.; Crooke, S. T. Determination of the Role of the Human RNase H1 in the Pharmacology of DNA-like Antisense drugs. J. Biol. Chem. 2004, 279, 17181-17189.
39. Sambrook, J.; Fritsch, E. F.; Maniatis, T. Molecular Cloning: A laboratory Manual, 2nd Ed., Cold spring Harbor laboratory, Cold Spring Harbor, New York, 1989.
40. Iwai, S.i; Kataoka, S.; Wakasa, M.; Ohtsuka, E.; Nakamura, H. Recognition of 2′-Hydroxyl Groups by Escherichia Coli Ribonuclease H1. FEBS Lett. 1995, 368, 315-320.
41. Denisov, A. Y.; Noronha, A. M.; Wilds, C. J.; Trempe, J.-F.; Pon, R. T.; Gehring, K.; Damha, M. J. Solution Structure of an Arabinonucleic Acid (ANA)/RNA Duplex in a Chimeric Hairpin: Comparison with 2′-Fluoro-ANA/RNA and DNA/RNA Hybrids. Nucleic Acids Res. 2001, 29 4284-4293.
42. Koshkin, A.; Singh, S. S.; Nielsen, P.; Rajwanshi, V. K.; Kumar, R.; Meldgaard, M.; Olsen, C. E.; Wengel, J. LNA (Locked Nucleic Acids): Synthesis of the Adenine, Cytosine, Guanine, 5-methylcytosine, Thymine and Uracil Bicyclonucleoside Monomers, Oligomers, and Unprecedented Nucleic Acid Recognition. Tertrahedron 1998, 54, 3607-3630.
43. Morita, K.; Hasegawa, C.; Kaneko, M.; Tsutsumi, S.; Sone, J.; Ishikawa, T.; Imanishi, T.; Koizumi, M. 2′-O-,4′-C-Ethylene-Bridged Nucleic Acids (ENA): Highly Nuclease-Resistant and Thermodynamically Stable Oligonucleotides for Antisense Drug. Bioarg. Med. Chem. Lett. 2002, 12, 73-76.
44. Takagi, M.; Morita, K.; Nakai, D.; Nakagomi, R.; Tokui, T.; Koizumi, M. Enhancement of the Inhibitory Activity of oatp Antisense Oligonucleotides by Incorporation of 2′-O,4′-C-Ethylene-Bridged Nucleic Acids (ENA) without a Loss of Subtype Selectivity. Biochemistry 2004, 43, 4501-4510
45. Jepsen, J. S.; Pfundheller, H. M.; Lykkesfeld, A. E. Downregulation of p21(WAFI/CIP) and Estrogen Receptor α in MCF-7 Cells by Antisense Oligonucleotides Containing Locked Nucleic Acid (LNA). Oligonucleotides 2004, 14, 147-156.
46. Fluiter, K.; Frieden, M.; Vreijling, J.; Rosenbohm, C.; Wissel, M. B. D.; Christensen, S. M.; Koch, T.; Ørum, H.; Bass, F. ON the In Vitro and In Vivo Properties of Four Locked Nucleic Acid Nucleotides Incorporated into an Anti-H Ras Antisense Oligonucleotides. Chembiochem 2005, 6, 1-6.
47. Wahlestedt, C.; Salmi, P.; Good, L.; Kela, J.; Johnsson, T.; Hökfelt, T.; Broberger, C.; Porreca, F.; Lai, J.; Ren, K.; Sssipov, M.; Koshkin, A.; Jakobsen, N.; Skouv, J., Oerum, H.; Jacobsen, H.; Wengel, J. Proc. Natl. Acad. Sci. USA 2000, 97, 5633-5638.
48. Koizumi, M.; Takagi-Sato, M.; Ohuyama, R.; Araki, K.; Sun, W.; Nakai, D.; tsutsumi, S.; Kawai, K. Direct Comparison of In Vivo Antisense Activity of ENA Oligonucleotides Targeting PTP1B mRNA with That of 2′-O-(2-Methoxy)ethyl-Modified Oligonucleotides. Oligonucleotides 2006, 16, 253-262.
49. Jepsen, J. S.; Sorensen, M. D.; Wengel, J. Locked nucleic acid: A potent nucleic acid analog in therapeutics and biotechnology. Oligonucleotides 2004, 14, 130-146.
50. Imanishi, T.; Obika, S. BNAs: Novel Nucleic Acid Analog with a Bridged Sugar Moiety. Chem. Commun. 2002, 1653-1659.
51. Wengel, J. Synthesis of 3′-C- and 4′-C-Branched Oligonucleotidesand the Development of Locked Nucleic Acid (LNA). Acc. Chem. Res. 1999, 32, 301-310.
52. Goel, S.; Desai, K.; Maca̧pinlac, M.; Wadler, S.; Goldberg, G.; Fields, A.; Einstein, M.; Volterra, F.; Wong, B.; Martin, R.; Mani, S. A Phase I Safety And Dose Escalation Trial Of Docetaxel Combined With GEM®231, A Second Generation Antisense Oligonucleotide Targeting Protein Kinase A R1a In Patients With Advanced Solid Cancers, Invest. New Drugs 2006, 24, 125-134.
53. Chi, K. M.; E. Eisenhauer, L.; Fazli, E. C.; Jones, S. L.; Goldenberg, J.; Powers, M. E. Gleave. A Phase I Pharmacokinetic and Pharmacodynamic Study of OGX-011, a 2′-Methoxyethyl Antisense to Clusterin, in Patients with Localized Prostate Cancer Prior to Radical Prostatectomy. J. Natl. Cancer Inst. 2005, 97, 1287.
54. Kastelein, J. J. P.; Wedel, M. K.; Baker, B. F.; Su, J.; Bradley, J. A.; Yu, R. Z.; Chuang, E.; Graham, M. J.; Crooke, R. M. Potent Reduction of Apolipoprotein B and LDL Cholesterol by an Antisense Inhibitor of Apolipoprotein B. Circulation 2006, 114(16), 1729-35.
55. Sewell, L. K.; Geary, R. S.; Baker, B. F.; Glover, J. M.; Mant, T. G. K.; Yu, R. Z.; Tami, J. A.; Dorr, F. A Phase 1 Trial of Isis 10483 8, a 2′-Methoxyethyl Modified Antisense Oligonucleotide Targeting Tumor Necrosis Factor-alpha. J. Pharmacol. Exp. Therap. 2002, 303, 1334-43.
56. Allerson, C. R.; Sioufi, N., Jarres, R.; Prakash, T. P.; Naik, N.; Berdeja, A.; Wanders, L.; Griffey, R. H.; Swayze, E. E.; Blast, B. Fully 2′-Modified Oligonucleotide Duplexes with Improved In Vitro Potency and Stability Compared to Unmodified siRNA. J. Med. Chem. 2005, 48, 901-904.
57. Dande, P.; Prakash, T. P.; Sioufi, N.; Gaus, H.; Jarres, R.; Berdeja, A.; Swayze, E. E.; Griffey, R. H.; Bhat, B. Improving RNA Interference in Mammalian Cells by 4′-Thio-Modified Small Interfering RNA (siRNA): Effect on siRNA Activity and Nuclease Stability When Used in Combination with 2′-O-Alkyl Modifications. J. Med. Chem. 2006 49, 1624-1634.
58. Prakash, T. P.; Allerson, C. R.; Dande, P.; Vickers, T. A.; Sioufi, N.; Jarres, R.; Baker, B. F.; Swayze, E. E.; Giffey, R. H.; Bhat, B. Positional Effect of Chemical Modifications on siRNA Activity in Mammalian Cells. J. Med. Chem. 2005, 48, 4247-4253
59. Davis, S., Lollo, B.; Freier, S.; Esau, C. Improved targeting of miRNA with antisense oligonucleotides. Nucleic Acids Res. 2006, 34, 2294-2304.
60. Esau, C.; Davis, S.; Murray, S. F.; Yu, X. X.; Pandey, S. K.; Pear, M.; Watts, L.; Booten, S. L.; Graham, M.; McKay, R.; Subramaniam, A.; Propp, S.; Lollo, B. A.; Freier, S.; Bennett, C. F. miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab. 2006, 3, 87-98.